December 12, 2012
$42.9 million multi-state settlement with Pfizer
HARRISBURG - Pennsylvania today joined 32 Attorneys General in a $42.9 million multi-state settlement with Pfizer Inc., resolving allegations that the company unlawfully promoted its drugs, Zyvox and Lyrica.
Attorney General Linda Kelly, said that Pfizer allegedly engaged in unfair and deceptive practices to promote the prescription drug Zyvox by making misleading and unsubstantiated claims of the drug?s superiority that expanded the indications for the drug. Zyvox is an antibacterial agent approved to treat certain types of infections; including nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (commonly known as "MRSA") and complicated skin and skin structure infections due to MRSA.
The multi-state investigation also accuses Pfizer Inc. of engaging in unconscionable and deceptive practices marketing Lyrica for various off-label uses. Lyrica is a pain reliever approved by the FDA to treat certain types of neuropathy and neuralgia.
As part of the Consent Judgment, Pfizer agrees to reform how it markets and promotes Zyvox and Lyrica. Under the Consent Judgment, Pfizer Inc. shall not:
Pennsylvania will receive more than $2 million as part of the settlement, which will be used for future consumer protection purposes.
The investigation was led by the Texas Attorney General, with an Executive Committee consisting of the Attorneys General of Arizona, Illinois, Maryland, New Jersey, Pennsylvania, and South Carolina. Also participating in the settlement are Alabama, Arkansas, California, Colorado, Delaware, the District of Columbia, Florida, Hawaii, Idaho, Indiana, Kansas, Kentucky, Michigan, Montana, Nebraska, Nevada, New Mexico, North Carolina, Ohio, Rhode Island, South Dakota, Tennessee, Vermont, Washington, Virginia, and Wisconsin.
# # #